DCR RG1
Alternative Names: DCR-RG1Latest Information Update: 29 Dec 2021
At a glance
- Originator Dicerna Pharmaceuticals; Roche
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 22 Jan 2021 Early research in Hepatitis B in Switzerland (Parenteral) before January 2021 (Dicerna Pharmaceuticals' pipeline, January 2021)
- 22 Jan 2021 Early research in Hepatitis B in USA (Parenteral) before January 2021 (Dicerna Pharmaceuticals' pipeline, January 2021)